<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00767871</url>
  </required_header>
  <id_info>
    <org_study_id>SMCIRB2007-01-024</org_study_id>
    <nct_id>NCT00767871</nct_id>
    <nct_alias>NCT00461383</nct_alias>
  </id_info>
  <brief_title>Changes of Cerebral Glucose Metabolism and After 12 Weeks of Escitalpram Treatment in Panic Disorder</brief_title>
  <official_title>Changes of Cerebral Glucose Metabolism Associated With the Fear Network Activity Before and After 12 Weeks of Escitalpram Treatment in Panic Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Panic disorder is one of the most prevalent psychiatric disorders and recently abnormal fear
      network is known to be implicated in the pathophysiology of panic disorder. The fear network
      involves many brain regions such as amygdala, hippocampus, periaqueductal gray (PAG), locus
      coeruleus, parahippocampal gyrus, frontal cortex, and thalamus. Escitalopram, a highly
      selective serotonin reuptake inhibitor, is usually effective for panic dis order, but there
      is little information on how escitalopram affects the fear network.

      The specific aim of this study is to test the following hypotheses using 18F-FDG positron
      emission tomography (PET)

        1. Patients with panic disorder will show abnormal activity of the fear network compared to
           healthy comparison subjects.

        2. Patients with panic disorder will show normalized activity of the fear network after
           12-weeks of treatment with escitalopram.

        3. The changes of fear work after the treatment will be associated with psychological
           variables and neurohormones.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>18FDG-PET, PDSS &amp; HAM-A</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Panic Disorder</condition>
  <arm_group>
    <arm_group_label>Escitalopram</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>escitalopram (10-20mg) to panic patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lexapro</intervention_name>
    <description>12 week treatment with lexapro</description>
    <arm_group_label>Escitalopram</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  panic disorder

          -  20-60 years

        Exclusion Criteria:

          -  history of major psychosis (schizophrenia or bipolar disorder), social phobia,
             obsessive-compulsive disorder, and generalized anxiety disorder, and posttraumatic
             stress disorder. The acceptable score on the 17-item Hamilton Depression Rating Scale
             at entry into the study will be less than 17.

          -  patients and volunteers with alcohol dependence and current regular use of
             benzodiazepines will be excluded. Subjects with current or previous regular use of
             benzodiazepines will be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bum-Hee Yu, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2008</study_first_submitted>
  <study_first_submitted_qc>October 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2008</study_first_posted>
  <last_update_submitted>July 21, 2011</last_update_submitted>
  <last_update_submitted_qc>July 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2011</last_update_posted>
  <responsible_party>
    <name_title>Bum-Hee Yu, M.D. Ph.D. / Professor</name_title>
    <organization>Department of Psychiatry, Samsung Medical Center</organization>
  </responsible_party>
  <keyword>Panic disorder</keyword>
  <keyword>PET</keyword>
  <keyword>Escitaopram</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Panic Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

